Status:
COMPLETED
A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension
Lead Sponsor:
Mylan Bertek Pharmaceuticals
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study was to contrast the efficacy and safety of 3 dose levels of nebivolol vs. placebo, when added to a patient's existing antihypertensive medication(s) for 3 months, in patients...
Detailed Description
Following a washout of any previous beta-blocker medication, if applicable, supine, sitting, and standing cuff blood pressure and pulse rate, 24-hour ambulatory blood pressure monitoring (ABPM), ECG, ...
Eligibility Criteria
Inclusion
- Average sitting diastolic blood pressure (DBP) greater then or equal to 90 mmHg and less then or equal to 109 mmHg at screening and baseline, in patients on background antihypertensive therapy taking at least one and no more than two of either ACE inhibitor, ARB, or diuretic.
Exclusion
- Recent myocardial infarction or stroke
- Contraindications to beta-blocker therapy
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
End Date :
October 1 2003
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00200434
Start Date
October 1 2002
End Date
October 1 2003
Last Update
September 20 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mylan Pharmaceuticals Inc.
Morgantown, West Virginia, United States, 26505